EMA Authorised: Epysqli (Eculizumab) — Samsung Bioepis NL B.V.

View source ↗

Summary

Epilishi (Eculizumab) from Samsung Bioepis NL B.V. has been authorised by EMA for its indicated use in paroxysmal nocturnal hemoglobinuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• EPYSQLI (eculizumab-aagh)

Snippet

Status: Authorised. Therapeutic area: Hemoglobinuria, Paroxysmal. MAH: Samsung Bioepis NL B.V.. Decision date: 07/08/2026